About ASYMCHEM Company

The company is a world-leading CDMO company that provides one-stop services for high-quality R&D and production of global new drugs. With the mission of speeding up the launch of new drugs and extending the quality of life, we rely on continuous technological innovation to provide one-stop CMC services for domestic and foreign pharmaceutical companies and biotechnology companies throughout the drug life cycle, and accelerate the development and application of new drugs. The company actively explores and lays out emerging business segments such as chemical macromolecule CDMO, pharmaceutical CDMO, clinical CRO, biomacromolecule CDMO, technology export and synthetic biotechnology, making the company a professional one-stop customized service platform for all-round innovative drugs. The main products are small molecule CDMO services, chemical macromolecule CDMO business segment, pharmaceutical CDMO business segment, clinical CRO business segment, biomacromolecule CDMO business segment, technology export business segment, and synthetic biotechnology business segment. In 2019, the company won the “2018 Best Partner for the Transformation and Upgrading of Chinese Pharmaceutical Enterprises”. A total of 6 award-winning companies/organizations were selected in this selection. As the only pharmaceutical CDMO company on the list, the company received awards through various levels of screening with excellent quality and service, good reputation and reputation — this is also another time for the company to win this award. It won two awards, “China's Top 100 Pharmaceutical Industry” and “China's Top 20 Pharmaceutical Outsourcing Companies” in the “2018 China Pharmaceutical Industry Most Influential List” issued by the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce, fully demonstrating the company's strong competitiveness and strong growth as an industry benchmark.